Rates of relapses and serious adverse events in patients with GPA or MPA receiving rituximab for maintenance therapy: a multicentre, retrospective study

Gialouri C., Chalkia A., Koutsianas C., Chavatza K., Argyriou E., Panagiotopoulos A., Karamanakos A., Dimouli A., Orfanos P., Lagiou P., Thomas K., Tsalapaki C., Katsikas G., Boki K., Boumpas D., Petras D., Vassilopoulos D..

2024 EULAR Congress, 12-15 June 2024, Vienna, Austria.